Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1 [SKOV3 BARD1 siRNA-RNASeq]

ABSTRACT: Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1 [SKOV3 BARD1 siRNA-RNASeq]

PROVIDER: PRJNA1039889 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26815887_1.fastq.gz	Fastqsanger.gz
	SRR26815887_2.fastq.gz	Fastqsanger.gz
	SRR26815888_1.fastq.gz	Fastqsanger.gz
	SRR26815888_2.fastq.gz	Fastqsanger.gz
	SRR26815889_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1 [SKOV3 BARD1 siRNA-RNASeq]

Project description:Despite widespread use of anti-vascular endothelial growth factor (VEGF) antibody (AVA) for cancer therapy, most patients develop progressive disease after initial response. Therefore, novel strategies are needed to understand and overcome AVA resistance. Here, we identify an unexpected role of BRCA1-associated RING domain 1 (BARD1) in overcoming adaptive resistance to AVA. We investigated the effects of epigenetic modulation on cellular response to AVA; in particular, the molecular effects of both global and targeted DNA methylation. Using in vitro assays, BARD1 was identified as being specifically involved in angiogenesis. Sequential treatment with azacytidine overcame AVA therapy resistance in cancer models in vivo. We further demonstrated that specifically targeting BARD1 with either small-interfering RNA or CpG-targeted demethylation reduced tumor growth when combined with AVA therapy (compared with AVA alone) in mouse models of ovarian cancer. These results identify a previously unrecognized role for BARD1 in tumor angiogenesis and show that targeted restoration of BARD1 can enhance the efficacy of AVA therapy in cancer models.

2025-06-17 | GSE247654 | GEO

Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1 [OVCAR8ip1 BARD1 overexpression]

2025-06-16 | GSE247653 | GEO

Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1 [BeadChip expression]

2025-06-16 | GSE249415 | GEO

Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1 [OVCAR8ip1 BARD1 overexpression]

Project description:Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1 [OVCAR8ip1 BARD1 overexpression]

| PRJNA1039887 | ENA

Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1

Project description:Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1

| PRJNA1039884 | ENA

Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1 [methylation]

Project description:Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1 [methylation]

| PRJNA1039888 | ENA

Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1 [methylation]

Project description:Genome wide DNA methylation profiling of anti-VEGF resistant SKOV3 tumor samples treated with B20 and/or Azacytidine. The Illumina Infinium 450k Human DNA methylation Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 450,000 CpGs in SKOV3 tumors. Samples included 2 control IgG, 2 Azacytidine, 2 B20 and 2 B20+Azacytidine treated SKOV3ip1 tumors.

2025-06-17 | GSE247655 | GEO

Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1 [BeadChip expression]

Project description:Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1 [BeadChip expression]

| PRJNA1049004 | ENA

Gene expression profiling of anti-human VEGF-treated tumor xenografts formed by IGROV-1 or SKOV3 cells

Project description:This microarray experiment was designed to identify genes and pathways modulated in ovarian cancer xenografts treated with anti-human VEGF mAb (Bevacizumab). Tumors were established in NOD/SCID mice by s.c. injection of human ovarian cancer cells (IGROV-1 and SKOV3). Mice were treated with the anti-VEGF monoclonal antibody Bevacizumab or with PBS (control). Total RNA was extracted from tumor samples and hybridized on Affymetrix GeneChip™ PrimeView™ Human Gene Expression Arrays. Each sample was derived from a different mouse (n=5 mice/group). In order to evaluate the effects of the anti-human VEGF mAb in the two models, expression data of IGROV-1 and SKOV3 derived tumors were normalized and analyzed separately. Raw microarray data, preprocessed data matrix and results of differential expression analysis are available together with the applied protocols.

2019-12-16 | E-MTAB-7683 | biostudies-arrayexpress

siRNA-mediated Egr-3 knockdown in VEGF-treated HUVEC

Project description:Analysis of umbilical vein endothelial cells (HUVEC) treated with Egr-3 siRNA under the VEGF treatment for 0,1, and 4 h. Egr-3, a member of early growth response family, is immediately and dramatically induced by VEGF in HUVEC, which regulates expression of many genes related to endothelial activation.

2009-11-30 | GSE18913 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data